-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Novavax recently said it has launched its first Phase III clinical trial to assess the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373.
trial is being carried out in the UK and 10,000 participants aged between 18 and 84 are expected to be recruited over the next four to six weeks.
Gregory Glenn, head of research and development at Novavax, commented: "We are optimistic that high levels of SARS-CoV-2 transmission will continue in the UK and we are optimistic about this critical Phase III clinical trial."
of the study will support regulatory licensing applications in the EU and other countries.
50 percent of the participants will receive two doses, including 5 mcg of protein antigens and 50 mcg of Matrix-M advents, 21 days apart, and the other half will be given a placebo.
, according to Novavax, the trial aims to recruit at least 25 percent of participants over the age of 65 and give priority to those most affected by COVID-19.
, as many as 400 people will be vaccinated against seasonal influenza as part of the study to assess the potential benefits of co-medication.
.